CYDY - Gilead Stock: HIV Litigation Presents A Risk To Future Earnings

• Gilead's businesses have numerous struggles, especially its core HIV businesses, which can cost it billions.
• The company is focused on pivoting away from HIV and toward a growing oncology business, having spent $10s of billions to do so.
• The company will definitely grow revenue, but there's no guarantee of continued long-term earnings in a difficult business.
• We view Gilead Sciences as a cautious long opportunity until there's more clarity on litigation.

For further details see: